They are used to treat heart conditions such as High blood pressure (Hypertension), Angina (Chest pain), Heart failure, and Arrhythmias, as well as other conditions like Essential tremor, Migraines, and Glaucoma
Regulatory Standards Health Canada regulates natural health products (NHPs) closely
2000 Oct;12 Suppl 4:S74-9
At a glance Most common cause / nausea and vomiting from GLP-1 GI side effects reducing fluid intake and increasing fluid loss Incidence of nausea (semaglutide 2.4 mg) / approximately 44% of participants in the STEP-1 trial reported nausea Incidence of vomiting (semaglutide 2.4 mg) / approximately 24% in STEP-1, the primary driver of acute fluid loss Incidence of diarrhea (semaglutide 2.4 mg) / approximately 30% in STEP-1, contributing to electrolyte depletion First-line treatment / oral rehydration with electrolytes
Progress does not require perfection
Methods and materials Reagents Pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W.1419) was synthesized by Kelowna International Scientific Inc
